ASTRAZENECA PHARMA share price has zoomed 16% and is presently trading at Rs 7,392.2.
Meanwhile, the BSE HEALTHCARE index is at 37,847.9 (up 1.1%).
Among the top gainers in the BSE HEALTHCARE index today are Lupin (up 6.7%) and LAURUS LABS (up 4.9%).
ERIS LIFESCIENCES (down 1.2%) and SUVEN PHARMACEUTICALS (down 1.1%) are among the top losers today.
Over the last one year, ASTRAZENECA PHARMA has moved up from Rs 3,791.4 to Rs 7,392.2, registering a gain of Rs 3,600.9 (up 95.0%).
On the other hand, the BSE HEALTHCARE index has moved up from 25,627.6 to 37,847.9, registering a gain of 47.7% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Glenmark Pharma (up 97.0%), Lupin (up 95.0%) and ASTRAZENECA PHARMA (up 95.0%).
Must See: These Segments are Witnessing Incredible Growth with Modi's Push
The BSE Sensex is at 80,231.0 (up 0.3%).
The top gainers among the BSE Sensex today are HCl Tech. (up 3.0%) and ICICI Bank (up 2.0%). The most traded stocks in the BSE Sensex are HDFC Bank and Tata Steel.
In the meantime, NSE Nifty is at 24,349.0 (up 0.3%). HCl Tech. and ICICI Bank are among the top gainers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 65,205.1 to 80,231.0, registering a gain of 15,026.0 points (up 23.0%).
ASTRAZENECA PHARMA net profit grew 128.6% YoY to Rs 395 million for the quarter ended March 2024, compared to a profit of Rs 173 million a year ago. Net sales rose 34.6% to Rs 3,832 million during the period as against Rs 2,847 million in January-March 2023.
For the year ended March 2023, ASTRAZENECA PHARMA reported 61.2% increase in net profit to Rs 993 million compared to net profit of Rs 616 million during FY22. Revenue of the company grew 24.5% to Rs 10,030 million during FY23.
The current Price to earnings ratio of ASTRAZENECA PHARMA, based on rolling 12 month earnings, stands at 114.4.
Equitymaster requests your view! Post a comment on "ASTRAZENECA PHARMA Gains 16%; BSE HEALTHCARE Index Up 1.1%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!